Full CoverageTop news
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC
By Russ Conroy
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
All coverage
Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation
By Angus Liu
Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC
By Douglas Adkins
Pembrolizumab Receives FDA Approval for Treatment of Head and Neck Squamous Cell Carcinoma
By Alexandra Gerlach
FDA Approves Keytruda for PD-L1+ as Neoadjuvant Treatment
By Rachel Klemovitch
FDA Approves Keytruda for PD-L1 Positive Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
By Don Tracy
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
By Vandana Singh
KEYNOTE-689 Leads to FDA Approval of Perioperative Pembrolizumab in HNSCC
By Ravindra Uppaluri
FDA OKs Perioperative Pembrolizumab in HNSCC: Findings From KEYNOTE-689
By Ravindra Uppaluri
FDA Approves Keytruda as First Immune Checkpoint Inhibitor for Resectable Locally Advanced Head and Neck...
By Kamal Kohli
Merck Keytruda approved by USFDA for Advanced Head and Neck Cancer
By Kamal Kohli & Ruchika Sharma